This clinical trial is focused on studying the effects of a medication called Atogepant for the treatment of Migraine. Migraines are severe headaches that can cause intense throbbing or pulsing in one area of the head and are often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. The study will compare the effectiveness of Atogepant, which is taken as a tablet, to a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to evaluate how well Atogepant works in treating a single migraine attack. Participants will be randomly assigned to receive either Atogepant or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the initial phase. This helps ensure that the results are not influenced by expectations about the treatment. After this phase, there will be an “open-label extension,” where all participants will have the opportunity to receive Atogepant.

Throughout the study, participants will take the medication when they experience a migraine attack and will be monitored for their response to the treatment. The study will assess various outcomes, such as the relief of headache pain and the ability to return to normal activities. The trial aims to provide valuable information about the safety and effectiveness of Atogepant for people who suffer from migraines.